COMPANY

DermaSensor

Keywords: oncology diagnostics machine learning Skin Cancer Skin Melanoma

Location: Miami, FL · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Sep 9, 2026 Raise Private equity round: $5M (total, as published), announced Sep 9, 2026. Source: company's own press page. source ↗
Sep 1, 2026 Partnership Partnership / licensing announced Sep 1, 2026. Source: company's own press page. source ↗
Jun 10, 2026 Partnership Partnership / licensing announced Jun 10, 2026. Source: company's own press page. source ↗
Oct 8, 2024 Trial start Not phased (device or behavioral study): DermaSensor Postmarket Surveillance Study source ↗
Aug 17, 2020 Trial start —: DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer source ↗

Apr 11, 2027 (ESTIMATED) · Not phased · DermaSensor Postmarket Surveillance Study · NCT06666790

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $5.0M. Last 2 years.

Sep 9, 2026 Private equity round: $5M (total, as published), announced Sep 9, 2026. Source: company's own press page. source ↗
Sep 1, 2026 Partnership / licensing announced Sep 1, 2026. Source: company's own press page. source ↗
Jun 10, 2026 Partnership / licensing announced Jun 10, 2026. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06690086	DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer	Not listed	Completed	Aug 17, 2020	Dec 9, 2021 (actual)
NCT06666790	DermaSensor Postmarket Surveillance Study	Not phased (device or behavioral study)	Recruiting	Oct 8, 2024	Apr 11, 2027 (estimated)